CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2021

Jan 31, 2021

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: Chimeric Therapeutics Limited (ASX:CHM)

ABN: 68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Ms. Cynthia Elkins
Date of Appointment:	1 February 2021

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number	Class of Securities
Nil	Nil

• See chapter 19 for defined terms.

11/3/2002

Appendix 3X Page 1

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number	Class of Securities
Nil	Nil	Nil

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Employment Contract
Nature of interest	2,750,000* unlisted options granted subject to shareholder approval at the Company’s next shareholder meeting in accordance with the ASX Listing Rules. The options will be granted in accordance with the terms of the Company’s Omnibus Incentive Plan (OIP) and will include the following terms and conditions: Issue price: Nil; Exercise Price will be set at the closing share price the day prior to appointment date. Expiry Date: 4 years from the Company’s ASX listing date. Vesting conditions: Vested over 24 months from the Company’s ASX listing date. Voluntary escrow period: 24 months from the Company’s ASX listing date.
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	2,750,000* unlisted options

*issuance of these securities is subject to receipt of shareholder approval at the Company’s next shareholder meeting.

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002